4BB — 4Basebio Income Statement
0.000.00%
Last trade - 00:00
- £138.30m
- £141.61m
- £0.27m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 0.202 | 0.462 | 0.338 | 0.268 |
Cost of Revenue | ||||
Gross Profit | -0.028 | 0.274 | 0.269 | 0.239 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Depreciation and Amortization | ||||
Unusual Expense / Income | ||||
Other Operating Expenses | ||||
Total Operating Expenses | 0.622 | 1.08 | 3.87 | 6.11 |
Operating Profit | -0.42 | -0.622 | -3.53 | -5.84 |
Total Net Non Operating Interest Income / Expense | ||||
Net Income Before Taxes | -0.529 | -0.716 | -3.64 | -5.93 |
Provision for Income Taxes | ||||
Net Income After Taxes | -0.423 | -0.719 | -3.23 | -5.15 |
Net Income Before Extraordinary Items | ||||
Net Income | -0.423 | -0.719 | -3.23 | -5.15 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -0.423 | -0.719 | -3.23 | -5.15 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.034 | -0.058 | -0.263 | -0.418 |
Dividends per Share |